Johnson & Johnson announced another recall last week, this time for its antipsychotic Risperdal Consta, due to concerns that the drug may not be sterile.  The Risperdal recall comes on the heels of dozens of recalls in recent years, costing the Brunswick, N.J.-based company hundreds... Read More

The Wall Street Journal reports that off-label antipsychotic use in nursing homes is a major concern, as the U.S. government has lobbied health care providers to curtail non-approved use of these drugs in senior patients based on a heightened risk of injury and death. The... Read More

A new study reveals that antipsychotic medications, such as Risperdal (risperidone), which are being prescribed to a growing number of children, have been tied to serious side effects including increased risks for diabetes. This is not the first time that Risperdal side effects have been... Read More

The RT News Network reports that psychiatrists prescribe antipsychotic drugs like Risperdal and Abilify to children in one third of all visits – a rate three times higher than during the 1990s. They go on to say that 90 percent of these prescriptions are for... Read More

The Kentucky attorney general filed a Risperdal lawsuit in Jefferson County Court, on June 14, 2013, against Janssen Pharmaceuticals and Johnson & Johnson, claiming the companies concealed the harmful side effects of the drug. An antipsychotic medication intended for use of the treatment of schizophrenia,... Read More

Arkansas resident Carry Ball is suing Janssen Pharmaceuticals, Inc. and Johnson & Johnson based on allegations that the defendants designed, manufactured and sold a defective drug known as Risperdal, causing her to suffer permanent injuries. Ball contends that as a direct and proximate result of... Read More

In a new Risperdal lawsuit filed July 17, 2013, Chicago resident Michael Johnson claims that Ortho-McNeil Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J), should be held liable for his injuries. He brings counts of negligence, breach of warranties, and more, stating that after... Read More

According to a July 11, 2013 report in the Philadelphia Inquirer, the FDA is not acting fast enough to address the concerns surrounding Johnson & Johnson’s anti-psychotic drug Risperdal. Though over 400 Risperdal lawsuits have been filed in courts throughout the country, the agency has... Read More